Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05802420 | RECRUITING | Pancreatic Cancer

The Value of Molecular Residual Disease Monitoring Based on ctDNA in Advanced or Metastatic Pancreatic Cancer
Sponsor:

Peking Union Medical College Hospital

Brief Summary:

The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in advanced or metastatic pancreatic cancer. The main questions it aims to answer are: * prognostic value of baseline MRD; * the role of MRD dynamic changes after treatment in guiding treatment. Peripheral blood derived from participants will be obtained for MRD test before first-line chemotherapy initiation and at the first imaging assessment after chemotherapy.

Condition or disease

Pancreatic Cancer

Advanced Cancer

Metastatic Cancer

Intervention/treatment

Later-line therapy

Phase

NA

Study Type : INTERVENTIONAL
Estimated Enrollment : 100 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : The Value of Molecular Residual Disease Monitoring Based on ctDNA in Advanced or Metastatic Pancreatic Cancer
Actual Study Start Date : 2023-02-01
Estimated Primary Completion Date : 2025-02-01
Estimated Study Completion Date : 2025-02-01

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * patients with histologically confirmed unresectable advanced or metastatic pancreatic cancer;
  • * both sexes, age ≥18 years old;
  • * ECOG performance status score ≤2;
  • * the expected survival time was ≥3 months.
Exclusion Criteria
  • * a known diagnosis of pancreatic cancer other than ductal adenocarcinoma;
  • * treated with any systemic antitumor treatment before first-line chemotherapy onset;
  • * died or lost to follow-up within one month after the initiation of first-line chemotherpay;
  • * combined with other primary malignances.
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Advanced or Metastatic Pancreatic Cancer

Location Details

NCT05802420

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

China, Beijing

Peking Union Medical College Hospital

Beijing, Beijing, China, 100730